DUBLIN, Jan. 4, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the first authorized generic ...
Sucampo markets Amitiza ® (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and Amitiza 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult ...
BETHESDA, Md., Sept. 13 -- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced that the first patient has been enrolled in a Phase III study of lubiprostone ...
BETHESDA, Md., and DEERFIELD, Ill., May 27 Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals NorthAmerica, Inc. today announced that AMITIZA(R) (lubiprostone) 8 mcg capsulesare ...
BETHESDA, Md. & ABBOTT PARK, Ill.--(BUSINESS WIRE)-- Sucampo Pharmaceuticals, Inc. (“Sucampo”) (NASDAQ: SCMP) and Abbott (NYSE: ABT) today reported data from a phase 3 clinical efficacy trial in 124 ...
Amitiza (lubiprostone, from Sucampo and Takeda) 8mcg capsules are now available for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in women ≥18 years of age. A 24mcg capsule has ...
Bethesda, Md., and Deerfield, Ill., May 27, 2008 – Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that AMITIZA® (lubiprostone) 8 mcg ...
San Diego, CA – May 18, 2008 – New study results indicated that treatment with AMITIZA ® (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback